Rhythm Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update
Globe Newswire•03/11/2026•07:00 ET
0
Key Highlights
- ➤IMCIVREE revenue $92.1 million, up 29% sequentially in Q3 2026
- ➤U.S. IMCIVREE revenue $67.5 million, up 32% from Q2 2026
- ➤700-plus U.S. patient start forms received from more than 500 prescribers
- ➤Bivamelagon pivotal Phase 3 trial in acquired HO targeted by year-end 2026
- ➤LG Chem agreement amended for $350 million fixed payments and 1% royalty
- ➤Term loan facility provides access to up to $750 million over five years
Expert Statements
David Meeker, M.D., Chairman, Chief Executive Officer and President of Rhythm Pharmaceuticals
“Rhythm continues to make strong progress in bringing IMCIVREE(®) (setmelanotide) to patients with acquired hypothalamic obesity (HO), highlighted by continued commercial momentum in the United States. Our commercial launch in Japan represents another important milestone in a market with the potential to become our second largest”
David Meeker, M.D., Chairman, Chief Executive Officer and President of Rhythm Pharmaceuticals
“The strength of the U.S. launch through two quarters reinforces both the significant unmet need in acquired HO and our opportunity to transform care for patients living with this serious disease.”
David Meeker, M.D., Chairman, Chief Executive Officer and President of Rhythm Pharmaceuticals
“We are excited about advancing our next-generation MC4R agonists, beginning with bivamelagon. Strong clinical results have reinforced our confidence in its potential across multiple indications, and we look forward to initiating pivotal trials in acquired HO and Prader-Willi syndrome. Our restructured bivamelagon royalty agreement with LG Chem reflects our strong belief in the future potential of the portfolio. With a strong global foundation built on IMCIVREE, bivamelagon entering Phase 3 development and further development planned for RM-718, there is a clear and compelling path to long-term growth and value creation for Rhythm.”
-- Strong U.S. launch momentum for IMCIVREE(®) (setmelanotide) for acquired hypothalamic obesity (HO) continues with more than 700 patient start forms as of September 30, 2026 --
-- Third quarter 2026 net product revenue from global sales of IMCIVREE of $92.1 million, an increase of 29% from the prior quarter --
Get started
Create a free account to read the full story.